文献速递造血干细胞移植与细胞治疗白血病

儿童急性白血病造血细胞移植中供者KIR内容与匹配的研究

Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia.
PubMed 文献 · Blood Adv · 2020-01-01

该研究基于CIBMTR 2005至2016年数据,分析372例ALL和344例AML患儿接受无关供者移植的结局。采用Cox回归评估KIR配体错配、KIR基因内容(着丝粒B)、KIR2DS1错配及着丝粒B/端粒A,发现均与复发或无事生存无显著关联。这是儿童急性白血病供者KIR的最大分析,不支持在T细胞充足移植中利用KIR选择无关供者。

要点

  • 儿童ALL 372例、AML 344例接受无关供者移植,多数为缓解期清髓预处理、骨髓来源。
  • KIR配体错配、着丝粒B、KIR2DS1错配及着丝粒B/端粒A均与复发或无事生存无显著关联。
  • 在体内T细胞去除(血清治疗)队列中同样无显著关联。

核心结论

  • 该研究为儿童急性白血病供者KIR的最大分析,不支持在T细胞充足移植中利用KIR选择无关供者。

研究设计与样本

  • 回顾性分析2005至2016年CIBMTR报告的儿童急性淋巴细胞白血病(ALL;n=372)或急性髓系白血病(AML;n=344)接受无关供者(URD)移植的结局。
  • 采用Cox回归模型检验KIR配体错配、KIR基因内容(着丝粒B)、KIR2DS1错配及着丝粒B/端粒A。

主要发现

  • 在全部队列(ALL和AML)、AML或ALL分别分析中,上述KIR指标均与复发或无事生存无显著关联。
  • 在体内T细胞去除(即血清治疗)队列中,同样无显著关联。
  • 多数患儿在缓解期接受清髓预处理,干细胞来源为骨髓。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple models of donor killer immunoglobulin receptor (KIR) alloreactivity or KIR genotype have been reported to be protective against leukemia relapse after allogeneic transplantation. However, few studies have addressed this topic in the pediatric population. Here, we assessed the outcomes of allogeneic transplantation in children with acute lymphoblastic leukemia (ALL; n = 372) or acute myeloid leukemia (AML; n = 344) who received unrelated donor (URD) transplantation and were reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) from 2005 to 2016. As expected in this pediatric population, most patients underwent myeloablative conditioning while in remission and with bone marrow as a stem cell source. We tested KIR ligand mismatch, KIR gene content (centromeric [Cen] B), KIR2DS1 mismatching, and Cen B/telomeric A using Cox regression models and found that none were significantly associated with either relapse or disease-free survival when considering the entire cohort of patients (ALL and AML), AML, or ALL separately. Moreover, there was no significant association with outcomes in the in vivo T-cell-depleted (ie, serotherapy) cohort. This study, which is the largest analysis of donor KIR in the pediatric acute leukemia population, does not support the use of KIR in the selection of URDs for children undergoing T-replete transplantation.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Verneris MR, Miller JS, Hsu KC, et al. Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia. Blood Adv. 2020. PMID: 32267930. doi:10.1182/bloodadvances.2019001284

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。